X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
On April 20, the U.S. Supreme Court is set to hear a case that could have a broad impact on patent law, defining the boundaries for researchers who use competitors’ patents to develop new products and innovations. The dispute in Merck KGaA v. Integra LifeSciences I, Ltd.involves a “safe harbor” provision of the 1984 Hatch-Waxman Act intended to balance the need to protect patents against the desire to promote the invention of new drugs from existing patents. The act has spawned seemingly endless litigation between generic and brand-name manufacturers. This conflict � between Merck KGaA (which is not related to New Jersey-based Merck) and the tiny medical technology company Integra LifeSciences � does not pit arch-rival generic manufacturers against brand-name drug-makers. This case raises concerns among all members of the pharmaceutical industry using patented compounds to develop their own drugs � a practice common to research and development in the industry. JUST HOW FAR? The question before the Court is: How much patent infringement does the safe harbor allow? The answer will be a matter of degree rather than an outright prohibition. The case asks whether a company can conduct basic scientific research that mightone day lead to a drug review by the Food and Drug Administration, or whether the safe harbor is limited to research that is directly headed to the FDA. It is a high-stakes question for all players in the multibillion-dollar pharmaceutical industry, but its potential impact may have far broader consequences on patent law, ultimately defining the scope by which companies can experiment with each other’s patents when doing any kind of research. A RESEARCH DISPUTE Integra owned several patents on RGD tripeptides, a tiny protein that binds to molecules on a cell’s surface. In 1988, Merck used Integra’s patents to begin researching drugs that could hinder cancerous tumor growth. Merck conducted what is known in the industry as preclinical research, an exploratory phase preceding the development of actual drugs with potential for FDA approval. The research unearthed some promising possibilities that Merck hoped would one day lead to a drug approved by the FDA. Integra sued, alleging that Merck infringed on its patents. A jury sitting in federal court in California awarded Integra $15 million in damages. In 2003, the U.S. Court of Appeals for the Federal Circuit upheld the lower court’s ruling in Integra Lifesciences I, Ltd. v. Merck KGaA. “This court has not considered the question arising in this case, namely, whether the pre-clinical research conducted [by Merck] is exempt from liability for infringement under” the Hatch-Waxman exception, noted the Federal Circuit. Judge Randall Rader, writing for the majority, said that Merck’s experiments “did not supply information for submission” to the FDA, “but instead identified the best drug candidate to subject to future clinical testing under the FDA processes.” The majority found that Hatch-Waxman allowed patent infringements on a limited scale, mainly to produce generic drugs in preparation for FDA approval through modest use of an existing patent. In this instance, the court held, Merck’s infringement occurred at too early a stage. “The exemption viewed in this context does not endorse an interpretation . . . that would encompass drug development activities far beyond those necessary to acquire information for FDA approval of a patented pioneer drug already on the market,” the court held. Hatch-Waxman, added the court, “simply does not globally embrace all experimental activity that at some point, however attenuated, may lead to an FDA approval process.” Judge Sharon Prost joined the majority; Judge Pauline Newman concurred in part and dissented in part. SHIVER THROUGH THE INDUSTRY The decision sent a shiver through the pharmaceutical industry and beyond. “The big question is, how far back in time does the safe harbor go?” asks Brian Coggio of the New York office of Orrick Herrington & Sutcliffe. “What activities are covered?” Over the past two decades, courts have expanded the scope of the safe harbor to include a wider range of research, Coggio says. The Federal Circuit’s decision is a step back and could potentially block drug-makers from conducting preclinical research necessary for FDA approval, he says. “The pharmaceutical industry had a heart attack,” Coggio adds, because research on animals, for instance, is often a prerequisite for obtaining FDA approval to move on to clinical tests on people. He says that the panel’s opinion could be interpreted in a way that would leave drug-makers liable for conducting this early stage of research, a scenario that has the industry worried. The Department of Justice also joined the chorus of dissent. “The decision of the court of appeals reflects an incorrect view of the law,” the department wrote in a brief to the U.S. Supreme Court. The consequences will be dire, significantly restricting the development of new drugs, the Justice Department said. BALANCING ACT The issue is one that strikes at patent law’s balance of competing interests � protection of patent holders’ current innovation versus a desire to encourage future innovation from existing patents. In striking this balance, courts established a common law research exemption two centuries ago, allowing researchers to infringe on patents on a narrow scale in order to conduct research leading to innovations or derivative products � a point that Judge Newman emphasized in her dissent of the Merckdecision. “The right to conduct research . . . should not await expiration of the patent,” Newman wrote. “Yet today the court disapproves and essentially eliminates the common law research exemption. This change of law is ill-suited to today’s research-founded, technology-based economy.” HUGE IMPACT The impact of the majority’s ruling is “huge,” says Jeffrey Lewis of New York’s Patterson, Belknap, Webb & Tyler. “I have clients taking research out of the U.S.,” says Lewis, who is working on two amicus briefs for this case. He says his clients are canceling construction of domestic research facilities in favor of foreign locations where rules allow greater flexibility in using existing patents to create new products. Donald Dunner of D.C.’s Finnegan, Henderson, Farabow, Garrett & Dunner, who represents Merck KGaA, says that without the common law exception, Hatch-Waxman provided some refuge to drug-makers. The panel’s decision threatens this refuge. Although the Supreme Court need not rule on the common law exception, Lewis explains, the doctrine is built on the same underpinnings as the safe harbor exemption. Michael Bobelian ( [email protected]) is a reporter atNew York Law Journal , an ALM newspaper, where this article first appeared.

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at [email protected]

 
 

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.